Published on November 21, 2012 at 3:00 AM
PROTEONOMIX, INC. (OTCBB: PROT), a biotechnology company (the "Company") focused on developing therapeutics based upon the use of human cells and their derivatives, announced today that the University of Medicine & Dentistry of New Jersey (UMDNJ) in conjunction with the Company has commenced the screening of patients with End Stage Liver Disease (ESLD) for use in its clinical trial of UMK-121.
Michael Cohen, the Chief Executive Officer of the Company stated: "At least thirty (30) patients have been screened so far pursuant to inclusion and exclusion criteria approved by the Institutional Review Board as part of the protocol. The initiation of screening is the first step towards commencement of the clinical trial of UMK-121."
SOURCE Proteonomix, Inc.